Evaluation of Safety, Tolerability and Response of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)
ClinicalTrials.gov ID NCT07260162 – Sponsor Institut Cancerologie de l'Ouest – ClinicalTrials.gov – NCT07260162
Etudes cliniques
Explorez nos publications scientifiques, études cliniques et avancées en alpha-immunothérapie
-
-
Evaluation of Safety, Tolerability and Response of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)
ClinicalTrials.gov ID NCT07260162 – Sponsor Institut Cancerologie de l'Ouest – ClinicalTrials.gov – NCT07260162
-
Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5
Watabe, T.; Naka, S.; Shirakami, Y.; Kaneda, K.; Murakami, M.; Toyoshima, A.; Cardinale, J.; Giesel, F.L. Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5. Seminars in Nuclear Medicine 2025;55(6):947-954. DOI: 10.1053/j.semnuclmed.2025.09.005
-
First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial)
Watabe, T.; Mukai, K.; Naka, S.; Sasaki, H.; Kamiya, T.; Hayakawa, T.; Fukuhara, A.; Takano, T.; Shirakami, Y.; Ooe, K.; Shigeno, S.; Okamura, S.; Masumura, K.; Hida, E.; Haba, H.; Toyoshima, A.; Isohashi, K.; Shimomura, I.; Tomiyama, N. First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial). Journal of Nuclear Medicine 2025. – DOI: 10.2967/jnumed.125.270810
-
Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [211At]At-anti-CA-IX Antibody (ATO-101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care
Rousseau, C.; Baumgartner, P.; Heymann, M.-F.; Taupin, M.; Geffroy, M.; Chatal, J.- F.; Gautier, G.; Allam, N.; Gaschet, J.; Eychenne, R.; Guérard, F.; Gestin, J.-F.; Varmenot, N.; Chérel, M. Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [ 211 At]At-anti-CA-IX Antibody (ATO- 101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care. Cancers 2025;17(7),1190. DOI: 10.3390/cancers17071190
-
PERTINENCE – 89Zr-Girentuximab Imaging in Non-Muscle-Invasive Bladder Cancer
ClinicalTrials.gov ID NCT04897763 – Sponsor Institut Cancerologie de l’Ouest – ClinicalTrials.gov – NCT04897763
-
PERTINENCE: A Pilot Study to Assess Safety, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled Girentuximab in Non-Muscle Invasive Bladder Cancer
ClinicalTrials.gov ID: NCT04897763 Sponsor: Institut de Cancérologie de l’Ouest (ICO) Collaborator: Atonco ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT04897763
-
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
ClinicalTrials.gov ID: NCT03670966 – Sponsor: Fred Hutchinson Cancer Center – ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT03670966
-
211At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
ClinicalTrials.gov ID: NCT03128034 – Sponsor: Fred Hutchinson Cancer Center – ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT03128034